CASE DISCUSSION
Dapagliflozin in patients with Chronic Kidney Disease
Presented from India by Dr Satyanarayana Garre0
Likes
2977
Views
119
Shares
119
Bookmarks
0
Credit Points
0
Learning Hours
0
CPD/CME Points
0
Courses Completed
Case Description
Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor that has shown promise in the management of Chronic Kidney Disease (CKD) in patients with type 2 diabetes. Dapagliflozin has demonstrated efficacy in reducing the progression of CKD in individuals with type 2 diabetes by...
Case Summary
- The speaker discusses SGLT2 inhibitors, a relatively new class of anti-diabetic medications introduced around 2018-2019, highlighting their significant impact on managing diabetic kidney disease (DKD) and chronic kidney disease (CKD). They emphasize the breakthrough nature of these drugs, especially considering the limited concrete options available for handling these conditions in previous decades.
Speaker Profile
Dr Satyanarayana Garre
MBBS, MD, DNB( Nephrology) Apollo hospitals HyderabadDr. Satyanarayana Garre is a highly qualified nephrologist at Apollo Hospitals, Hyderabad, with an MBBS, MD, and DNB in Nephrology. He has extensive experience in diagnosing and managing complex kidney disorders, including chronic kidney disease, dialysis, and renal transplantation. Dr. Garre is known for his patient-centered approach and commitment to evidence-based nephrology care. His clinical expertise and academic background make him a trusted specialist in the field of kidney health.